M
8.73
0.27 (3.19%)
| Penutupan Terdahulu | 8.46 |
| Jumlah Dagangan | 25,168 |
| Harga / Buku (P/B) | 0.260 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -4.99 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1,071.43% |
| Nisbah Semasa (MRQ) | 1.35 |
| Aliran Tunai Operasi (OCF TTM) | -21.71 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -12.26 M |
| Pulangan Atas Aset (ROA TTM) | -62.45% |
| Pulangan Atas Ekuiti (ROE TTM) | -214.79% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Moleculin Biotech, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.6 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | -2.0 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | -4.0 |
| Persekitaran Makro | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | -0.58 |
|
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company’s Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.42% |
| % Dimiliki oleh Institusi | 6.13% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |